[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.168.111.191. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Lin  JS, Piper  M, Perdue  LA,  et al.  Screening for Colorectal Cancer: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05203-EF-1.
2.
Zauber  A, Knudsen  A, Rutter  CM, Lansdorp-Vogelaar  I, Kuntz  KM.  Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05203-EF-2.
3.
Howlader  N, Noone  AM, Krapcho  M,  et al, eds. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/. Accessed April 21, 2016.
4.
Shapiro  JA, Klabunde  CN, Thompson  TD, Nadel  MR, Seeff  LC, White  A.  Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey.  Cancer Epidemiol Biomarkers Prev. 2012;21(6):895-904.PubMedGoogle ScholarCrossref
5.
Inadomi  JM, Vijan  S, Janz  NK,  et al.  Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.  Arch Intern Med. 2012;172(7):575-582.PubMedGoogle ScholarCrossref
6.
Lin  JS, Piper  MA, Perdue  LA,  et al.  Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force.  JAMA. doi:10.1001/jama.2016.3332.Google Scholar
7.
Henrikson  NB, Webber  EM, Goddard  KA,  et al.  Family history and the natural history of colorectal cancer: systematic review.  Genet Med. 2015;17(9):702-712.PubMedGoogle ScholarCrossref
8.
Levin  B, Lieberman  DA, McFarland  B,  et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.  CA Cancer J Clin. 2008;58(3):130-160.PubMedGoogle ScholarCrossref
9.
Brawley  OW.  Colorectal cancer control: providing adequate care to those who need it.  J Natl Cancer Inst. 2014;106(4):dju075.PubMedGoogle ScholarCrossref
10.
Dignam  JJ, Colangelo  L, Tian  W,  et al.  Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project.  J Natl Cancer Inst. 1999;91(22):1933-1940.PubMedGoogle ScholarCrossref
11.
Cooper  GS, Koroukian  SM.  Racial disparities in the use of and indications for colorectal procedures in Medicare beneficiaries.  Cancer. 2004;100(2):418-424.PubMedGoogle ScholarCrossref
12.
Knudsen  AB, Zauber  AG, Rutter  CM,  et al.  Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force.  JAMA. doi:10.1001/jama.2016.6828.Google Scholar
13.
Imperiale  TF, Ransohoff  DF, Itzkowitz  SH,  et al.  Multitarget stool DNA testing for colorectal-cancer screening.  N Engl J Med. 2014;370(14):1287-1297.PubMedGoogle ScholarCrossref
14.
Holme  Ø, Løberg  M, Kalager  M,  et al.  Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial.  JAMA. 2014;312(6):606-615.PubMedGoogle ScholarCrossref
15.
Nishihara  R, Wu  K, Lochhead  P,  et al.  Long-term colorectal-cancer incidence and mortality after lower endoscopy.  N Engl J Med. 2013;369(12):1095-1105.PubMedGoogle ScholarCrossref
16.
Premarket approval (PMA) for Epi proColon. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P130001. Accessed April 21, 2016.
17.
Church  TR, Wandell  M, Lofton-Day  C,  et al; PRESEPT Clinical Study Steering Committee, Investigators and Study Team.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.  Gut. 2014;63(2):317-325.PubMedGoogle ScholarCrossref
18.
Lansdorp-Vogelaar  I, Gulati  R, Mariotto  AB,  et al.  Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.  Ann Intern Med. 2014;161(2):104-112.PubMedGoogle ScholarCrossref
19.
Centers for Disease Control and Prevention (CDC).  Vital signs: colorectal cancer screening test use: United States, 2012.  MMWR Morb Mortal Wkly Rep. 2013;62(44):881-888.PubMedGoogle Scholar
20.
Abdelsattar  ZM, Wong  SL, Regenbogen  SE, Jomaa  DM, Hardiman  KM, Hendren  S.  Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening.  Cancer. 2016;122(6):929-934.PubMedGoogle ScholarCrossref
21.
Premarket approval application (PMA) approval letter for Cologuard. US Food and Drug Administration. http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130017a.pdf. Accessed April 20, 2016.
22.
Redwood  DG, Asay  ED, Blake  ID,  et al.  Stool DNA testing for screening detection of colorectal neoplasia in Alaska Native people.  Mayo Clin Proc. 2016;91(1):61-70.PubMedGoogle ScholarCrossref
23.
Quintero  E, Castells  A, Bujanda  L,  et al; COLONPREV Study Investigators.  Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.  N Engl J Med. 2012;366(8):697-706.PubMedGoogle ScholarCrossref
24.
Kaminski  MF, Bretthauer  M, Zauber  AG,  et al.  The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer.  Endoscopy. 2012;44(7):695-702.PubMedGoogle ScholarCrossref
25.
Colonoscopy vs Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) [NCT01239082]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01239082. Accessed May 27, 2016.
26.
Colonoscopy and FIT as Colorectal Cancer Screening Test in the Average Risk Population [NCT02078804]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02078804. Accessed May 27, 2016.
27.
US Preventive Services Task Force.  Screening for colorectal cancer: US Preventive Services Task Force recommendation statement.  Ann Intern Med. 2008;149(9):627-637.PubMedGoogle ScholarCrossref
28.
Rex  DK, Johnson  DA, Anderson  JC, Schoenfeld  PS, Burke  CA, Inadomi  JM; American College of Gastroenterology.  American College of Gastroenterology guidelines for colorectal cancer screening 2009 [published correction appears in Am J Gastroenterol. 2009;104(6):1613].  Am J Gastroenterol. 2009;104(3):739-750.PubMedGoogle ScholarCrossref
29.
Burt  RW, Cannon  JA, David  DS,  et al; National Comprehensive Cancer Network.  Colorectal cancer screening.  J Natl Compr Canc Netw. 2013;11(12):1538-1575.PubMedGoogle ScholarCrossref
30.
Wilt  TJ, Harris  RP, Qaseem  A; High Value Care Task Force of the American College of Physicians.  Screening for cancer: advice for high-value care from the American College of Physicians.  Ann Intern Med. 2015;162(10):718-725.PubMedGoogle ScholarCrossref
31.
Clinical preventive service recommendation: colorectal cancer. American Academy of Family Physicians. http://www.aafp.org/patient-care/clinical-recommendations/all/colorectal-cancer.html. Accessed April 20, 2016.
32.
Canadian Task Force on Preventive Health Care.  Recommendations on screening for colorectal cancer in primary care.  CMAJ. 2016;188(5):340-348.PubMedGoogle ScholarCrossref
US Preventive Services Task Force
Recommendation Statement
June 21, 2016

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force
JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989
Abstract

Importance  Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134 000 persons will be diagnosed with the disease, and about 49 000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 73 years.

Objective  To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer.

Evidence Review  The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screening methods.

Findings  The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States.

Conclusions and Recommendations  The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history (C recommendation).

×